Skip To Main Content
Kete Campbell-Coker on Muck Rack

Kete Campbell-Coker

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kete

Contact Kete, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

|
By James Rucker, Tim Mantingh, Jess Kerr-Gaffney, Catherine Bird, Petrina Chu, Nadav Liam Modlin, Sadie Hambleton, Diede Fennema, Elliot Hampsey, Dimosthenis Tsapekos, Rebecca Thomas, Hassan Jafari, Camilla Ridley Day, Anya Borissova, Miranda KnoxAlex Lloyd, Mathieu Seynaeve, Michael Creed, Luke Baxter, Raphael PZ Rifkin-Zybutz, Matt Butler, Luke A Jelen, Ben Carter, Allan Young, Kete Campbell-Coker, Paige Seath, Rebecca Hignett, Joseph Cattell, Theo Boardman-Pretty, Famia Askari
| Nature Verified
Abstract Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health Service (NHS) site in England.
Open in Who Shared Issue with article?
See all 1 articles